Srivastava Shekhar, Li Zhai, Lin Lin, Liu GongXin, Ko Kyung, Coetzee William A, Skolnik Edward Y
Skirball Institute, New York University Medical Center, 540 First Avenue, New York, NY 10016, USA.
Mol Cell Biol. 2005 May;25(9):3630-8. doi: 10.1128/MCB.25.9.3630-3638.2005.
Myotubularins (MTMs) belong to a large subfamily of phosphatases that dephosphorylate the 3' position of phosphatidylinositol 3-phosphate [PI(3)P] and PI(3,5)P(2). MTM1 is mutated in X-linked myotubular myopathy, and MTMR2 and MTMR13 are mutated in Charcot-Marie-Tooth syndrome. However, little is known about the general mechanism(s) whereby MTMs are regulated or the specific biological processes regulated by the different MTMs. We identified a Ca(2+)-activated K channel, K(Ca)3.1 (also known as KCa4, IKCa1, hIK1, or SK4), that specifically interacts with the MTMR6 subfamily of MTMs via coiled coil (CC) domains on both proteins. Overexpression of MTMR6 inhibited K(Ca)3.1 channel activity, and this inhibition required MTMR6's CC and phosphatase domains. This inhibition is specific; MTM1, a closely related MTM, did not inhibit K(Ca)3.1. However, a chimeric MTM1 in which the MTM1 CC domain was swapped for the MTMR6 CC domain inhibited K(Ca)3.1, indicating that MTM CC domains are sufficient to confer target specificity. K(Ca)3.1 was also inhibited by the PI(3) kinase inhibitors LY294002 and wortmannin, and this inhibition was rescued by the addition of PI(3)P, but not other phosphoinositides, to the patch pipette solution. PI(3)P also rescued the inhibition of K(Ca)3.1 by MTMR6 overexpression. These data, when taken together, indicate that K(Ca)3.1 is regulated by PI(3)P and that MTMR6 inhibits K(Ca)3.1 by dephosphorylating the 3' position of PI(3)P, possibly leading to decreased PI(3)P in lipid microdomains adjacent to K(Ca)3.1. K(Ca)3.1 plays important roles in controlling proliferation by T cells, vascular smooth muscle cells, and some cancer cell lines. Thus, our findings not only provide unique insights into the regulation of K(Ca)3.1 channel activity but also raise the possibility that MTMs play important roles in the negative regulation of T cells and in conditions associated with pathological cell proliferation, such as cancer and atherosclerosis.
肌管素(MTMs)属于一个庞大的磷酸酶亚家族,可使磷脂酰肌醇3 - 磷酸[PI(3)P]和PI(3,5)P(2)的3' 位去磷酸化。MTM1在X连锁肌管性肌病中发生突变,MTMR2和MTMR13在夏科 - 马里 - 图斯综合征中发生突变。然而,关于MTMs的调控一般机制或不同MTMs所调控的特定生物学过程,人们了解甚少。我们鉴定出一种钙激活钾通道K(Ca)3.1(也称为KCa4、IKCa1、hIK1或SK4),它通过两种蛋白上的卷曲螺旋(CC)结构域与MTMs的MTMR6亚家族特异性相互作用。MTMR6的过表达抑制了K(Ca)3.1通道活性,且这种抑制作用需要MTMR6的CC结构域和磷酸酶结构域。这种抑制具有特异性;与之密切相关的MTM1并不抑制K(Ca)3.1。然而,一种将MTM1的CC结构域替换为MTMR6的CC结构域的嵌合MTM1抑制了K(Ca)3.1,这表明MTM的CC结构域足以赋予靶标特异性。PI(3)激酶抑制剂LY294002和渥曼青霉素也抑制K(Ca)3.1,并且通过向膜片钳吸管溶液中添加PI(3)P(而非其他磷酸肌醇)可挽救这种抑制作用。PI(3)P也可挽救MTMR6过表达对K(Ca)3.1的抑制。综合这些数据表明,K(Ca)3.1受PI(3)P调控,且MTMR6通过使PI(3)P的3' 位去磷酸化来抑制K(Ca)3.1,这可能导致与K(Ca)3.1相邻的脂质微区中PI(3)P减少。K(Ca)3.1在控制T细胞、血管平滑肌细胞和一些癌细胞系的增殖中起重要作用。因此,我们的发现不仅为K(Ca)3.1通道活性的调控提供了独特见解,还提出了MTMs在T细胞的负调控以及与病理性细胞增殖相关的病症(如癌症和动脉粥样硬化)中起重要作用的可能性。